Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DNAI1 Primary Ciliary Dyskinesia: Genetic Testing, Patient Finding and Increasing Disease Awareness Program

NCT06172374 is registered in ClinicalTrials.gov with ReCode Therapeutics as lead sponsor.

NCT NCT06172374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06172374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DNAI1 Primary Ciliary Dyskinesia: Genetic Testing, Patient Finding and Increasing Disease Awareness Program
Lead sponsor
ReCode Therapeutics
Phase
Observational
Overall status
Active, not recruiting
Start date
August 31, 2023
Completion date
December 31, 2025
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary ciliary dyskinesia